

VSIG1 (D-14): sc-169796

BACKGROUND

VSIG1 (V-set and immunoglobulin domain-containing protein 1), also known as cell surface A33 antigen or glycoprotein A34, is a 387 amino acid protein belonging to the junctional adhesion molecule (JAM) family. VSIG1 is a single-pass type I membrane protein that contains one Ig-like C2-type domain and one Ig-like V-type domain. The N-terminal extracellular domain of VSIG1 is thought to contain seven possible phosphorylation sites while the C-terminal intracellular domain contains eleven. Heavily glycosylated on the N-terminal domain, VSIG1 is expressed at high levels solely in stomach mucosa and testis. VSIG1 has also been found in some gastric and ovarian cancers and esophageal carcinomas.

REFERENCES

- Gerhard, D.S., Wagner, L., Feingold, E.A., Shenmen, C.M., Grouse, L.H., Schuler, G., Klein, S.L., Old, S., Rasooly, R., Good, P., Guyer, M., Peck, A.M., Derge, J.G., Lipman, D., Collins, F.S., Jang, W., Sherry, S., et al. 2004. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). *Genome Res.* 14: 2121-2127.
- Nikolaidis, N., Klein, J. and Nei, M. 2005. Origin and evolution of the Ig-like domains present in mammalian leukocyte receptors: insights from chicken, frog, and fish homologues. *Immunogenetics* 57: 151-157.
- Scanlan, M.J., Ritter, G., Yin, B.W., Williams, C., Cohen, L.S., Coplan, K.A., Fortunato, S.R., Frosina, D., Lee, S.Y., Murray, A.E., Chua, R., Filonenko, V.V., Sato, E., Old, L.J. and Jungbluth, A.A. 2006. Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. *Cancer Immun.* 6: 2.
- Bechtel, S., Rosenfelder, H., Duda, A., Schmidt, C.P., Ernst, U., Wellenreuther, R., Mehrle, A., Schuster, C., Bahr, A., Blöcker, H., Heubner, D., Hoerlein, A., Michel, G., Wedler, H., Köhler, K., Ottenwälder, B., Poustka, A., Wiemann, S. and Schupp, I. 2007. The full-ORF clone resource of the German cDNA Consortium. *BMC Genomics* 8: 399.

CHROMOSOMAL LOCATION

Genetic locus: VSIG1 (human) mapping to Xq22.3; Vsig1 (mouse) mapping to X F1.

SOURCE

VSIG1 (D-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an extracellular domain of VSIG1 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-169796 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

VSIG1 (D-14) is recommended for detection of VSIG1 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with VSIG6 or VSIG8.

VSIG1 (D-14) is also recommended for detection of VSIG1 in additional species, including equine.

Suitable for use as control antibody for VSIG1 siRNA (h): sc-91325, VSIG1 siRNA (m): sc-155230, VSIG1 shRNA Plasmid (h): sc-91325-SH, VSIG1 shRNA Plasmid (m): sc-155230-SH, VSIG1 shRNA (h) Lentiviral Particles: sc-91325-V and VSIG1 shRNA (m) Lentiviral Particles: sc-155230-V.

Molecular Weight of VSIG1: 42 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.